PHASE 1/2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ARO-DIMERPA IN ADULT SUBJECTS WITH MIXED HYPERLIPIDEMIA
- Registry ID
- ARODIMERPA-1001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ARROWHEAD PHARMACEUTICALS, INC.
- Start date
- 2026-07-14
- Last update
- 2026-06-12
Conditions
Related clinical trials
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENLICITIDE DECANOATE COADMINISTERED WITH ROSUVASTATIN IN ADULTS WITH HYPERLIPIDEMIA
- A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFECT OF AZD0780 ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENT
- A PHASE 1B SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY OF VERVE-201 IN PATIENTS WITH REFRACTORY HYPERLIPIDEMIA
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BEMPEDOIC ACID (ETC-1002) 180 MG/DAY AS ADD-ON TO EZETIMIBE THERAPY IN PATIENTS WITH ELEVATED LDL-C
- A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY ON LDL-C OF EVOLOCUMAB (AMG 145) IN SUBJECTS WITH HIV AND WITH HYPERLIPIDEMIA AND/OR MIXED DYSLIPIDEMIN
- A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF EVOLOCUMAB (AMG 145) IN COMBINATION WITH STATIN THERAPY IN DIABETIC SUBJECTS WITH HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
View on source registry